Analysis Review and Prioritization
The February and March AIMS SIG meetings focused on reviewing an initial analysis of the AIMS data. These initial analyses aimed to determine key areas of focus and areas to gain a deeper understanding of the data, and initial discussions of implications of the analysis for practice.
The objective of the February AIMS SIG meeting was to review the initial analysis of the AIMS data, raise any questions about the analysis and begin discussions about areas of focus. The group reviewed a broad analysis of the AIMS data, including analysis of drugs and drug classes, event categories and contributing factors involved in a higher proportion of events.
The group discussed opportunities for improvement in reporting and data collection in the AIMS program, including clarifying in the platform the difference between drugs prescribed and dispensed, and reducing the selection of “other” in reporting for the event type and contributing factors fields.
The importance of emphasizing the value of reporting medication events to collect data from a broader number of pharmacies was also raised. The challenge of many reports coming from a relatively small number of pharmacies was noted as a general challenge to medication event reporting.
Between the February and March meetings, the AIMS SIG members were asked to review the analysis presented at the February meeting and, using a structured survey completed independently, recommend areas of the analysis for the AIMS SIG to focus on. These recommendations were used as a starting point for the March meeting discussion.
The objective of the March meeting was to continue review of data and suggest and prioritize areas for in-depth analysis. The areas of analysis discussed at this meeting focused on drug and drug classes with higher proportion of higher harm events, contributing factors and sub factors that appeared most frequently, drugs dispensed with a higher proportion of events, and common event types overall.
The AIMS SIG discussed their interest in specific drugs and drug classes, as well as better understanding the severity of harm level associated with incidents. The group also discussed their interest in learning more about demographics of patients involved in medication incidents and the potential impacts of the COVID-19 pandemic on reporting.